Does the media prefer MGTX or NAMS?

In the previous week, NewAmsterdam Pharma had 2 more articles in the media than MeiraGTx. MarketBeat recorded 5 mentions for NewAmsterdam Pharma and 3 mentions for MeiraGTx. NewAmsterdam Pharma's average media sentiment score of 0.87 beat MeiraGTx's score of 0.63 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MGTX or VKTX?

In the previous week, Viking Therapeutics had 2 more articles in the media than MeiraGTx. MarketBeat recorded 5 mentions for Viking Therapeutics and 3 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.63 beat Viking Therapeutics' score of 0.60 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CRNX or MGTX?

In the previous week, Crinetics Pharmaceuticals had 4 more articles in the media than MeiraGTx. MarketBeat recorded 7 mentions for Crinetics Pharmaceuticals and 3 mentions for MeiraGTx. Crinetics Pharmaceuticals' average media sentiment score of 1.12 beat MeiraGTx's score of 0.63 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MeiraGTx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KNSA or MGTX?

In the previous week, Kiniksa Pharmaceuticals International and Kiniksa Pharmaceuticals International both had 3 articles in the media. Kiniksa Pharmaceuticals International's average media sentiment score of 1.14 beat MeiraGTx's score of 0.63 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals International 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MeiraGTx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MeiraGTx (MGTX) Competitors

$9.14 -0.07 (-0.76%)

Closing price 04:00 PM Eastern

Extended Trading

$9.32 +0.18 (+2.01%)

As of 05:56 PM Eastern

Compare

MGTX vs. NAMS, CPRX, VKTX, CRNX, and KNSA

Should you buy MeiraGTx stock or one of its competitors? MarketBeat compares MeiraGTx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MeiraGTx include NewAmsterdam Pharma (NAMS), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Crinetics Pharmaceuticals (CRNX), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry.

How does MeiraGTx compare to NewAmsterdam Pharma?

MeiraGTx (NASDAQ:MGTX) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 7.5% of MeiraGTx shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, NewAmsterdam Pharma had 2 more articles in the media than MeiraGTx. MarketBeat recorded 5 mentions for NewAmsterdam Pharma and 3 mentions for MeiraGTx. NewAmsterdam Pharma's average media sentiment score of 0.87 beat MeiraGTx's score of 0.63 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MeiraGTx has a net margin of -151.12% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	-1,065.47%	-54.96%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

MeiraGTx has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market.

MeiraGTx has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	10.40	-$114.20M	-$1.48	N/A
NewAmsterdam Pharma	$22.50M	152.39	-$203.82M	-$1.79	N/A

MeiraGTx currently has a consensus target price of $25.83, indicating a potential upside of 182.64%. NewAmsterdam Pharma has a consensus target price of $48.60, indicating a potential upside of 65.70%. Given MeiraGTx's higher probable upside, equities research analysts plainly believe MeiraGTx is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

NewAmsterdam Pharma beats MeiraGTx on 9 of the 16 factors compared between the two stocks.

How does MeiraGTx compare to Catalyst Pharmaceuticals?

MeiraGTx (NASDAQ:MGTX) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Catalyst Pharmaceuticals has higher revenue and earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	10.40	-$114.20M	-$1.48	N/A
Catalyst Pharmaceuticals	$588.99M	6.51	$214.33M	$1.74	18.01

Catalyst Pharmaceuticals has a net margin of 37.08% compared to MeiraGTx's net margin of -151.12%. Catalyst Pharmaceuticals' return on equity of 35.76% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	-1,065.47%	-54.96%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 7.5% of MeiraGTx shares are owned by insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MeiraGTx presently has a consensus price target of $25.83, indicating a potential upside of 182.64%. Catalyst Pharmaceuticals has a consensus price target of $32.00, indicating a potential upside of 2.11%. Given MeiraGTx's stronger consensus rating and higher possible upside, research analysts plainly believe MeiraGTx is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

MeiraGTx has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

In the previous week, MeiraGTx had 2 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 3 mentions for MeiraGTx and 1 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.43 beat MeiraGTx's score of 0.63 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
MeiraGTx	Positive
Catalyst Pharmaceuticals	Positive

Summary

Catalyst Pharmaceuticals beats MeiraGTx on 11 of the 17 factors compared between the two stocks.

How does MeiraGTx compare to Viking Therapeutics?

MeiraGTx (NASDAQ:MGTX) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

MeiraGTx has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	10.40	-$114.20M	-$1.48	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A

In the previous week, Viking Therapeutics had 2 more articles in the media than MeiraGTx. MarketBeat recorded 5 mentions for Viking Therapeutics and 3 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.63 beat Viking Therapeutics' score of 0.60 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

MeiraGTx presently has a consensus target price of $25.83, indicating a potential upside of 182.64%. Viking Therapeutics has a consensus target price of $93.60, indicating a potential upside of 237.30%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

Viking Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. Viking Therapeutics' return on equity of -71.31% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	-1,065.47%	-54.96%
Viking Therapeutics	N/A	-71.31%	-65.35%

MeiraGTx has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 7.5% of MeiraGTx shares are owned by insiders. Comparatively, 5.3% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

MeiraGTx and Viking Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does MeiraGTx compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and MeiraGTx (NASDAQ:MGTX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

MeiraGTx has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	469.96	-$465.32M	-$5.13	N/A
MeiraGTx	$81.39M	10.40	-$114.20M	-$1.48	N/A

Crinetics Pharmaceuticals has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Comparatively, 7.5% of MeiraGTx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Crinetics Pharmaceuticals had 4 more articles in the media than MeiraGTx. MarketBeat recorded 7 mentions for Crinetics Pharmaceuticals and 3 mentions for MeiraGTx. Crinetics Pharmaceuticals' average media sentiment score of 1.12 beat MeiraGTx's score of 0.63 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MeiraGTx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MeiraGTx has a net margin of -151.12% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Crinetics Pharmaceuticals' return on equity of -43.96% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
MeiraGTx	-151.12%	-1,065.47%	-54.96%

Crinetics Pharmaceuticals presently has a consensus target price of $76.13, suggesting a potential upside of 121.81%. MeiraGTx has a consensus target price of $25.83, suggesting a potential upside of 182.64%. Given MeiraGTx's higher possible upside, analysts plainly believe MeiraGTx is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Crinetics Pharmaceuticals and MeiraGTx tied by winning 8 of the 16 factors compared between the two stocks.

How does MeiraGTx compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and MeiraGTx (NASDAQ:MGTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

In the previous week, Kiniksa Pharmaceuticals International and Kiniksa Pharmaceuticals International both had 3 articles in the media. Kiniksa Pharmaceuticals International's average media sentiment score of 1.14 beat MeiraGTx's score of 0.63 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MeiraGTx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kiniksa Pharmaceuticals International presently has a consensus price target of $60.86, suggesting a potential upside of 23.52%. MeiraGTx has a consensus price target of $25.83, suggesting a potential upside of 182.64%. Given MeiraGTx's higher probable upside, analysts clearly believe MeiraGTx is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to MeiraGTx's net margin of -151.12%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
MeiraGTx	-151.12%	-1,065.47%	-54.96%

Kiniksa Pharmaceuticals International has higher revenue and earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	5.59	$59.01M	$0.90	54.74
MeiraGTx	$81.39M	10.40	-$114.20M	-$1.48	N/A

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Comparatively, 7.5% of MeiraGTx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Kiniksa Pharmaceuticals International has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

Summary

Kiniksa Pharmaceuticals International beats MeiraGTx on 11 of the 16 factors compared between the two stocks.

Get MeiraGTx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGTX vs. The Competition

Export

Metric	MeiraGTx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$852.93M	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.31%	2.67%	5.61%
P/E Ratio	-6.18	18.83	24.65	23.63
Price / Sales	10.40	290.77	498.98	103.49
Price / Cash	N/A	120.20	43.05	54.72
Price / Book	-130.57	8.00	10.43	6.70
Net Income	-$114.20M	$23.89M	$3.56B	$337.26M
7 Day Performance	-2.66%	-3.49%	-1.39%	-1.41%
1 Month Performance	-6.92%	1.03%	0.86%	1.15%
1 Year Performance	33.24%	34.39%	19.42%	22.61%

MeiraGTx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGTX MeiraGTx	2.9574 of 5 stars	$9.14 -0.8%	$25.83 +182.6%	+45.7%	$852.93M	$81.39M	N/A	300	Positive News
NAMS NewAmsterdam Pharma	2.8045 of 5 stars	$31.15 -7.5%	$48.00 +54.1%	+50.7%	$3.94B	$22.50M	N/A	4
CPRX Catalyst Pharmaceuticals	3.7983 of 5 stars	$31.28 +0.1%	$32.00 +2.3%	+21.3%	$3.82B	$588.99M	17.97	80	Positive News
VKTX Viking Therapeutics	3.1736 of 5 stars	$29.49 -9.9%	$93.60 +217.4%	+6.0%	$3.80B	N/A	N/A	20
CRNX Crinetics Pharmaceuticals	3.191 of 5 stars	$33.29 -6.4%	$76.13 +128.7%	+8.3%	$3.75B	$18.07M	N/A	210	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGTX) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MeiraGTx (MGTX) Competitors

MGTX vs. NAMS, CPRX, VKTX, CRNX, and KNSA

How does MeiraGTx compare to NewAmsterdam Pharma?

Summary

How does MeiraGTx compare to Catalyst Pharmaceuticals?

Summary

How does MeiraGTx compare to Viking Therapeutics?

Summary

How does MeiraGTx compare to Crinetics Pharmaceuticals?

Summary

How does MeiraGTx compare to Kiniksa Pharmaceuticals International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGTX vs. The Competition

MeiraGTx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MeiraGTx (MGTX) Competitors

MGTX vs. NAMS, CPRX, VKTX, CRNX, and KNSA

How does MeiraGTx compare to NewAmsterdam Pharma?

Do insiders and institutionals have more ownership in MGTX or NAMS?

Does the media prefer MGTX or NAMS?

Is MGTX or NAMS more profitable?

Which has more risk and volatility, MGTX or NAMS?

Which has stronger earnings and valuation, MGTX or NAMS?

Do analysts rate MGTX or NAMS?

Summary

How does MeiraGTx compare to Catalyst Pharmaceuticals?

Which has higher valuation and earnings, MGTX or CPRX?

Is MGTX or CPRX more profitable?

Do insiders & institutionals have more ownership in MGTX or CPRX?

Do analysts rate MGTX or CPRX?

Which has more volatility and risk, MGTX or CPRX?

Does the media prefer MGTX or CPRX?

Summary

How does MeiraGTx compare to Viking Therapeutics?

Which has stronger valuation & earnings, MGTX or VKTX?

Does the media prefer MGTX or VKTX?

Do analysts recommend MGTX or VKTX?

Is MGTX or VKTX more profitable?

Which has more risk and volatility, MGTX or VKTX?

Do institutionals & insiders have more ownership in MGTX or VKTX?

Summary

How does MeiraGTx compare to Crinetics Pharmaceuticals?

Which has preferable valuation and earnings, CRNX or MGTX?

Which has more volatility and risk, CRNX or MGTX?

Do insiders & institutionals hold more shares of CRNX or MGTX?

Does the media refer more to CRNX or MGTX?

Is CRNX or MGTX more profitable?

Do analysts recommend CRNX or MGTX?

Summary

How does MeiraGTx compare to Kiniksa Pharmaceuticals International?

Does the media refer more to KNSA or MGTX?

Do analysts recommend KNSA or MGTX?

Is KNSA or MGTX more profitable?

Which has stronger earnings & valuation, KNSA or MGTX?

Do institutionals and insiders hold more shares of KNSA or MGTX?

Which has more volatility & risk, KNSA or MGTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGTX vs. The Competition

MeiraGTx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools